{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:07:32Z","timestamp":1785240452581,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:31:49Z","timestamp":1777930309000},"page":"e868-e875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?"],"prefix":"10.1016","volume":"26","author":[{"given":"Andre Costa","family":"Meireles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma Martinho","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Korin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"D\u00edaz-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7235-1334","authenticated-orcid":false,"given":"Guilherme Fleury","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.clml.2026.04.006_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.04.006_bib0002","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","article-title":"Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes","volume":"6","author":"Castellino","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2023-190383","article-title":"Trends in survival outcomes for mantle cell lymphoma in the era of novel therapies","volume":"142","author":"Ermann","year":"2023","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.clml.2026.04.006_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.clml.2026.04.006_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"10.1016\/j.clml.2026.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.clml.2026.04.006_bib0008","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.006_bib0009","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network","volume":"41","author":"Hermine","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.04.006_bib0012","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.04.006_bib0013","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.04.006_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.006_bib0015","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.04.006_bib0016","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.006_bib0017","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.006_bib0018","unstructured":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). - ASCO [Internet]. Accessed: March 25, 2026. Available at: https:\/\/www.asco.org\/abstracts-presentations\/123330."},{"issue":"4","key":"10.1016\/j.clml.2026.04.006_bib0019","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/bloodadvances.2025018527","article-title":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma","volume":"10","author":"Wang","year":"2026","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2026.04.006_bib0020","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent Non-Hodgkin lymphoma or mantle-cell lymphoma with Bendamustine Plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0021","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance Rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.006_bib0023","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2019-129404","article-title":"Maintenance Rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with Bendamustine + Rituximab without autologous transplant","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"10441","key":"10.1016\/j.clml.2026.04.006_bib0024","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.04.006_bib0025","unstructured":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma | New England Journal of Medicine [Internet]. Accessed January 11, 2026 Available at: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2201817."},{"issue":"20","key":"10.1016\/j.clml.2026.04.006_bib0026","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib Plus Bendamustine-Rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.006_bib0027","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-023-01520-7","article-title":"Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium","volume":"16","author":"Vose","year":"2023","journal-title":"J Hematol Oncol J Hematol Oncol"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2026.04.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-212973","volume":"144","author":"Fenske","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.04.006_bib0029","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10020","key":"10.1016\/j.clml.2026.04.006_bib0030","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"10121","key":"10.1016\/j.clml.2026.04.006_bib0031","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.clml.2026.04.006_bib0032","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2026.04.006_bib0033","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.006_bib0034","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.clml.2026.04.006_bib0035","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.006_bib0036","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2025-663","article-title":"Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1\/2 study","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0037","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a Phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.006_bib0038","article-title":"MCL-1493: fixed-duration outpatient subcutaneous Mosunetuzumab + Polatuzumab Vedotin shows robust efficacy in a Phase 2 study of relapsed\/refractory (R\/R) post-BTK inhibitor mantle cell lymphoma (MCL)","volume":"25","author":"Wang","year":"2025","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.clml.2026.04.006_bib0039","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.04.006_bib0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.006_bib0041","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma (MCL): primary analysis of the MCL cohort from TRANSCEND NHL 001, a Phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.006_bib0042","article-title":"Clinical outcomes of patients with B-cell Non-Hodgkin lymphoma in real-world settings: findings from the hemato-oncology Latin America observational registry study","volume":"8","author":"Pavlovsky","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.006_bib0043","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.htct.2024.02.012","article-title":"REALM study: a retrospective evaluation of treatment patterns in patients with mantle cell lymphoma in a routine single private practice in Brazil","volume":"46","author":"Bellesso","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2026.04.006_bib0044","doi-asserted-by":"crossref","first-page":"13204","DOI":"10.1002\/cam4.6009","article-title":"Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.clml.2026.04.006_bib0045","first-page":"4583","article-title":"Mantle cell lymphoma: a North Indian tertiary care centre experience","volume":"17","author":"Das","year":"2016","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.clml.2026.04.006_bib0046","unstructured":"WHO Model List of Essential Medicines - 23rd list, 2023 [Internet]. Accessed February 2, 2026. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02."},{"key":"10.1016\/j.clml.2026.04.006_bib0047","doi-asserted-by":"crossref","DOI":"10.1590\/s2237-96222025v34e20240203.pt","article-title":"Impacto financeiro da aquisi\u00e7\u00e3o centralizada de rituximabe pelo Minist\u00e9rio da Sa\u00fade para tratamento de linfomas, 2015-2022: estudo explorat\u00f3rio","volume":"34","author":"Martins","year":"2025","journal-title":"Epidemiol E Servi\u00e7os Sa\u00fade"},{"issue":"7","key":"10.1016\/j.clml.2026.04.006_bib0048","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.04.006_bib0049","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00277-023-05342-y","article-title":"Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia","volume":"102","author":"Hegde","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.04.006_sbref0050","series-title":"Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton\u2019s Tyrosine Kinase Inhibitor Therapy","author":"Wang","year":"2023"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:55:46Z","timestamp":1785239746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001060"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}